| scholarly article | Q13442814 |
| P50 | author | Lindsey Roeker | Q82493945 |
| Martha Grogan | Q88589959 | ||
| Suzanne R Hayman | Q96475488 | ||
| Joseph A Dearani | Q96650505 | ||
| Arleigh McCurdy | Q114300392 | ||
| Richard J Rodeheffer | Q114434641 | ||
| Sudhir S Kushwaha | Q117224545 | ||
| Angela Dispenzieri | Q37838558 | ||
| Morie A Gertz | Q57052163 | ||
| Robert A Kyle | Q66385695 | ||
| Martha Q Lacy | Q66419394 | ||
| P2093 | author name string | Richard Daly | |
| Robert Frantz | |||
| Christopher McGregor | |||
| Brooks Edwards | |||
| P2860 | cites work | Outcome of heart transplantation in patients with amyloid cardiomyopathy | Q81504165 |
| Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients | Q82765188 | ||
| Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis | Q84595891 | ||
| Should we avoid heart transplantation in cardiomyopathy due to radiotherapy/chemotherapy or amyloidosis? The devil is in the details | Q85599232 | ||
| Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment | Q26827340 | ||
| Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. | Q34437074 | ||
| Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score | Q34450910 | ||
| Diagnosis and management of the cardiac amyloidoses | Q34454122 | ||
| Amyloidosis: pathogenesis and new therapeutic options. | Q35111771 | ||
| Long term results of heart transplantation in patients with amyloid heart disease | Q35378115 | ||
| High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement | Q35750326 | ||
| Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis | Q35886289 | ||
| Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish | Q37054932 | ||
| Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis | Q37624857 | ||
| Current state of cardiac amyloidosis | Q38074540 | ||
| Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. | Q38343098 | ||
| Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. | Q38370866 | ||
| Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation | Q39128093 | ||
| Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey | Q41169312 | ||
| Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey | Q41240614 | ||
| Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure | Q42166191 | ||
| Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement | Q43520391 | ||
| New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes | Q44572498 | ||
| Cardiac transplantation for amyloid heart disease: the United Kingdom experience | Q45101029 | ||
| Outcomes of adults with restrictive cardiomyopathy after heart transplantation | Q46298655 | ||
| Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. | Q46909999 | ||
| Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the spanish registry for heart transplantation | Q47751835 | ||
| Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. | Q53463848 | ||
| Solid Organ Transplantation in AL Amyloidosis | Q58853141 | ||
| High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis | Q60976474 | ||
| Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival | Q71774378 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 380-388 | |
| P577 | publication date | 2016-06-01 | |
| P1433 | published in | World journal of transplantation | Q27725045 |
| P1476 | title | Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience | |
| P478 | volume | 6 |
| Q39172346 | Heart transplantation in cardiac amyloidosis |
| Q55023498 | Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. |
| Q39272596 | Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response |
| Q38779623 | New and developing therapies for AL amyloidosis |
| Q99361678 | Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience |
| Q98947237 | Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management |
Search more.